Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
16,463,909
-
Total 13F shares
-
16,829,467
-
Share change
-
+2,008,037
-
Total reported value
-
$541,869,734
-
Put/Call ratio
-
61%
-
Price per share
-
$32.20
-
Number of holders
-
66
-
Value change
-
+$65,277,706
-
Number of buys
-
40
-
Number of sells
-
22
Institutional Holders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT) as of Q3 2020
As of 30 Sep 2020 RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT) had 66 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 16,829,467 shares of stock of the company.
Largest 10 holders included Svennilson Peter, PRICE T ROWE ASSOCIATES INC /MD/, WELLINGTON MANAGEMENT GROUP LLP, REGENTS OF THE UNIVERSITY OF CALIFORNIA, BlackRock Inc., Alphabet Inc., VANGUARD GROUP INC, Avoro Capital Advisors LLC, Schonfeld Strategic Advisors LLC, and ACUTA CAPITAL PARTNERS, LLC.
This table shows 66 institutional shareholders of the security as of 30 Sep 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.